Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy[1],[2] ...
The uniformity of delivered dose, or dose content uniformity, was assessed to understand the performance of the Sirdupla generic product versus the Seretide Evohaler innovator product. Analytical ...
Mylan N.V. has announced that it has launched the first bioequivalent alternative to GlaxoSmithKline's Seretide® Evohaler® (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla™ ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Bronchial asthma is a common long-lasting disease where the airways become inflamed, making them more sensitive and less open. Currently, around 300 million people across the world are affected by ...
LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...
Glenmark Pharmaceuticals today said it has received three observations from the US health regulator for its Pithampur, Indore plant. (Source: website) Glenmark Pharmaceuticals has entered into an ...
The generic drug, montelukast should be offered to people ahead of combination inhalers such as GlaxoSmithKline's Seretide, in a bid to save the NHS millions of pounds, according to draft guidance ...
-- Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results